• Apple, Inc AAPL
  • S&P 500 ETF Trust SPDR SPY
  • Alphabet Inc. - Class A Shares GOOGL
  • Microsoft Corporation MSFT
  • Meta Platforms Inc META
  • Netflix, Inc. NFLX
  • Amazon.com Inc. AMZN
  • Spotify Technology SA SPOT
    bmy-img

    Bristol-Myers Squibb Company, Common Stock

    BMY

    NYQ

    $44.03

    -$0.08

    (-0.18%)

    1D
    Industry: Pharmaceuticals Sector: Health Care

    Analyst Forecast

    Overview Returns Financials Ratios News FAQs

    Price Chart

    Key Metrics

    Market Cap info-icon
    This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
     $89.25B
    P/E Ratio info-icon
    This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
     NM
    Volume info-icon
    This is the total number of shares traded during the most recent trading day.
     15.47M
    Avg Volume info-icon
    This is the average number of shares traded during the most recent 30 days.
     14.52M
    Dividend Yield info-icon
    This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
     5.39%
    Beta info-icon
    This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
     0.44
    52-week Range info-icon
    This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
    $43.33 L
    $64.39 H
    $44.03

    About Bristol-Myers Squibb Company, Common Stock

    Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. more

    Industry: PharmaceuticalsSector: Health Care

    Returns

    Time FrameBMYSectorS&P500
    1-Week Return-2.02%1.89%1.51%
    1-Month Return-7.96%5.68%5.65%
    3-Month Return-10.67%1.18%6.8%
    6-Month Return-11.37%15.01%18.16%
    1-Year Return-30.98%13.5%29.33%
    3-Year Return-25.35%24.42%33.21%
    5-Year Return11.11%80.35%100.99%
    10-Year Return20.38%193.83%237.54%

    Financials

    Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
    Total Revenue26.14B42.52B46.38B46.16B45.01B[{"date":"2019-12-31","value":56.37,"profit":true},{"date":"2020-12-31","value":91.66,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.51,"profit":true},{"date":"2023-12-31","value":97.03,"profit":true}]
    Cost of Revenue8.08B11.77B9.94B10.14B10.69B[{"date":"2019-12-31","value":68.61,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":84.43,"profit":true},{"date":"2022-12-31","value":86.1,"profit":true},{"date":"2023-12-31","value":90.83,"profit":true}]
    Gross Profit18.07B30.75B36.45B36.02B34.31B[{"date":"2019-12-31","value":49.57,"profit":true},{"date":"2020-12-31","value":84.36,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":98.84,"profit":true},{"date":"2023-12-31","value":94.15,"profit":true}]
    Gross Margin69.10%72.31%78.57%78.04%76.24%[{"date":"2019-12-31","value":87.95,"profit":true},{"date":"2020-12-31","value":92.03,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.32,"profit":true},{"date":"2023-12-31","value":97.03,"profit":true}]
    Operating Expenses12.15B28.57B27.91B26.92B26.12B[{"date":"2019-12-31","value":42.54,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.69,"profit":true},{"date":"2022-12-31","value":94.22,"profit":true},{"date":"2023-12-31","value":91.42,"profit":true}]
    Operating Income5.46B5.13B10.16B10.33B17.24B[{"date":"2019-12-31","value":31.69,"profit":true},{"date":"2020-12-31","value":29.74,"profit":true},{"date":"2021-12-31","value":58.92,"profit":true},{"date":"2022-12-31","value":59.9,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
    Total Non-Operating Income/Expense(1.15B)(13.42B)(3.40B)(3.85B)267.00M[{"date":"2019-12-31","value":-428.84,"profit":false},{"date":"2020-12-31","value":-5025.84,"profit":false},{"date":"2021-12-31","value":-1271.54,"profit":false},{"date":"2022-12-31","value":-1440.82,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
    Pre-Tax Income4.97B(6.87B)8.10B7.71B8.44B[{"date":"2019-12-31","value":58.95,"profit":true},{"date":"2020-12-31","value":-81.41,"profit":false},{"date":"2021-12-31","value":95.95,"profit":true},{"date":"2022-12-31","value":91.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
    Income Taxes1.51B2.12B1.08B1.37B400.00M[{"date":"2019-12-31","value":71.33,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":51.04,"profit":true},{"date":"2022-12-31","value":64.41,"profit":true},{"date":"2023-12-31","value":18.83,"profit":true}]
    Income After Taxes3.46B(8.99B)7.01B6.34B8.04B[{"date":"2019-12-31","value":43.03,"profit":true},{"date":"2020-12-31","value":-111.88,"profit":false},{"date":"2021-12-31","value":87.24,"profit":true},{"date":"2022-12-31","value":78.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
    Income From Continuous Operations6.49B(8.99B)7.01B6.34B8.30B[{"date":"2019-12-31","value":78.16,"profit":true},{"date":"2020-12-31","value":-108.33,"profit":false},{"date":"2021-12-31","value":84.48,"profit":true},{"date":"2022-12-31","value":76.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
    Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
    Net Income3.44B(8.99B)6.99B6.33B8.03B[{"date":"2019-12-31","value":42.85,"profit":true},{"date":"2020-12-31","value":-112.09,"profit":false},{"date":"2021-12-31","value":87.15,"profit":true},{"date":"2022-12-31","value":78.84,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
    EPS (Diluted)4.676.447.507.807.39[{"date":"2019-12-31","value":59.87,"profit":true},{"date":"2020-12-31","value":82.56,"profit":true},{"date":"2021-12-31","value":96.15,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":94.74,"profit":true}]

    Ratios

    Liquidity

    These ratios help you determine the liquidity of the company. Higher is better.

    BMY
    Cash Ratio 0.37
    Current Ratio 1.11
    Quick Ratio 0.99

    Asset Efficiency

    These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

    BMY
    ROA (LTM) 5.39%
    ROE (LTM) -25.33%

    Liabilities

    These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

    BMY
    Debt Ratio Lower is generally better. Negative is bad. 0.83
    Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.17
    Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. 6.01

    Valuation

    These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

    BMY
    Trailing PE NM
    Forward PE 6.93
    P/S (TTM) 2.17
    P/B 3.32
    Price/FCF 35
    EV/R 2.82
    EV/Ebitda 6.56
    PEG 0.08

    News

    Trade Tracker: Goldman Sachs, Bristol Myers and TJX

    The Investment Committee shares their latest portfolio moves.

    17 May, 2024 a 5:08 pm CNBC

    Could this pharmaceutical company reach a trillion-dollar valuation?

    The post Could this pharmaceutical company reach a trillion-dollar valuation? appeared on BitcoinEthereumNews.com . Only seven companies have reached the trillion-dollar goal post–six technology companies and one Saudi Arabian oil conglomerate. However, this Big Pharma member is not far behind and could skyrocket to a trillion-dollar valuation relatively soon. Today, we’ll explore Eli Lilly (NYSE: LLY), the odds of it reaching the market capitalization of $1 trillion, and why you should consider investing in it right now. What is the state of the pharmaceutical industry in 2024? Despite the fear that pharmaceutical industry sales would plummet after the global pandemic was over, this did not happen. In fact, global sales of pharmaceutical products are consistently on the rise, no matter how the rest of the economy performs. Pharmaceutical Manufacturing Market Size 2020 to 2030. Source: precedenceresearch.com That said, there is the risk of an imminent “patent cliff” as some of the world’s most in-demand drugs have their patent expiry dates by 2030, such as Merck‘s Keytruda (2028), Bristol Myers Squibb & Pfizer‘s Eliquis (2027-2029), and Regeneron & Bayer‘s Eylea (2025-2026).

    16 May, 2024 a 7:02 pm Bitcoin Ethereum News

    Bristol Myers Squibb’s CAR T cell therapy Breyanzi approved by U.S. Food and Drug Administration for relapsed or refractory follicular lymphoma

    The U.S. Food and Drug Administration (FDA) has …

    16 May, 2024 a 4:32 pm EIN News Food

    New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis

    Bristol Myers Squibb (NYSE:BMY) today announced new four-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. After four years of continuous treatment, Week 208 responses for Psoriasis Area and Severity Index (PASI) 75 and 90 were 71.7% and 47.5%, respectively, and 57.2% for static Physician’s Jetzt den vollständigen Artikel lesen

    16 May, 2024 a 2:26 pm Wallstreet:Online

    7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs

    It’s no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stocks? The answers, of course, are as varied as the companies leveraging AI. Many will leverage AI for the process of drug discovery. AI is much more efficient at identifying compounds with potential efficacy for a given disease or disorder. Others are utilizing AI to improve the development process for validation assays, the tests used to identify compounds. The use cases go on and on. There’s also the question of how AI will affect individual pharma stocks. The answer there, too, will be varied. AI will serve to raise the prices of some stocks while others will not be so fortunate. Let’s take a look at seven pharma stocks to buy that leverage AI and what investors can expect. Schrodinger (SDGR) Source: Sisacorn / Shutterstock.com Schrodinger (NASDAQ: SDGR ) continues to develop its physics-based computational platform, which heavily leverages artificial intelligence.

    16 May, 2024 a 11:15 am InvestorPlace

    Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma | BMY Stock News

    FDA grants accelerated approval for Breyanzi in relapsed/refractory follicular lymphoma. 95.7% response rate, with 77.1% responders at 18 months. Learn more!

    16 May, 2024 a 12:57 am Stock Titan

    Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma

    Bristol Myers Squibb (NYSE: BMY) today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received two or more prior lines of systemic therapy. This Jetzt den vollständigen Artikel lesen

    16 May, 2024 a 12:57 am Wallstreet:Online

    Discover more

    Tsla

    Tesla, Inc.
    aaple

    Apple, Inc.
    GOOGL

    Alphabet Inc. - Class A Shares
    META

    Meta Platforms Inc
    AMZN

    Amazon.com Inc.
    Microsoft

    Microsoft Corporation
    NVDA

    NVIDIA Corporation
    BRK

    Berkshire Hathaway Inc. Hld B
    LLY

    Eli Lilly and Company

    FAQs

    What is Bristol-Myers Squibb Company share price today?

    Bristol-Myers Squibb Company (BMY) share price today is $44.03

    Can Indians buy Bristol-Myers Squibb Company shares?

    Yes, Indians can buy shares of Bristol-Myers Squibb Company (BMY) on Vested. To buy Bristol-Myers Squibb Company from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BMY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

    Can Fractional shares of Bristol-Myers Squibb Company be purchased?

    Yes, you can purchase fractional shares of Bristol-Myers Squibb Company (BMY) via the Vested app. You can start investing in Bristol-Myers Squibb Company (BMY) with a minimum investment of $1.

    How to invest in Bristol-Myers Squibb Company shares from India?

    You can invest in shares of Bristol-Myers Squibb Company (BMY) via Vested in three simple steps:

    • Click on Sign Up or Invest in BMY stock at the top of this page
    • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
    • Transfer USD funds to your US Brokerage account and start investing in Bristol-Myers Squibb Company shares
    What is Bristol-Myers Squibb Company 52-week high and low stock price?

    The 52-week high price of Bristol-Myers Squibb Company (BMY) is $64.39. The 52-week low price of Bristol-Myers Squibb Company (BMY) is $43.33.

    What is Bristol-Myers Squibb Company price-to-earnings (P/E) ratio?

    The price-to-earnings (P/E) ratio of Bristol-Myers Squibb Company (BMY) is NM

    What is Bristol-Myers Squibb Company price-to-book (P/B) ratio?

    The price-to-book (P/B) ratio of Bristol-Myers Squibb Company (BMY) is 3.32

    What is Bristol-Myers Squibb Company dividend yield?

    The dividend yield of Bristol-Myers Squibb Company (BMY) is 5.39%

    What is the Market Cap of Bristol-Myers Squibb Company?

    The market capitalization of Bristol-Myers Squibb Company (BMY) is $89.25B

    What is Bristol-Myers Squibb Company’s stock symbol?

    The stock symbol (or ticker) of Bristol-Myers Squibb Company is BMY

    Feedback

    Signup to access all features and start your US investing journey!

    • Open your account in minutes
    • Take your portfolio global, starting at just $1
    Get started

    Add ticker to compare

    white-logo

    222 N. Sepulveda Blvd, Suite 10-124, 
El Segundo, CA 90245, USA

    5 Vivekanand Villa, 139 S V Road, Andheri West, Mumbai, Mumbai City, Maharashtra, India, 400058

    help@vestedfinance.co | +919513375607

    Google_Play_Store
    Apple_store
    instagram twitter linkedin

    Company

    Explore Products

    MOST POPULAR ON VESTED

    Popular US Stocks 1

    Apple Microsoft Alphabet (Google) Amazon NVIDIA Meta Platforms (Facebook) Berkshire Hathaway Tesla Eli Lilly Visa UnitedHealth Walmart JPMorgan Chase Exxon Mobil Broadcom Johnson & Johnson Mastercard Procter & Gamble Oracle Home Depot Chevron Adobe Merck Costco AbbVie

    Popular US ETFs 2

    SPDR S&P 500 ETF Trust iShares Core S&P 500 ETF Vanguard S&P 500 ETF Vanguard Total Stock Market ETF Invesco QQQ Trust Series I Vanguard FTSE Developed Markets ETF Vanguard Value ETF Vanguard Total Bond Market ETF iShares Core MSCI EAFE ETF iShares Core U.S. Aggregate Bond ETF Vanguard Growth ETF iShares Russell 1000 Growth ETF Vanguard FTSE Emerging Markets ETF iShares Core MSCI Emerging Markets ETF iShares Core S&P Mid-Cap ETF Vanguard Dividend Appreciation ETF iShares Core S&P Small-Cap ETF SPDR Gold Shares Vanguard Total International Stock ETF Vanguard Total International Bond ETF Vanguard Mid-Cap ETF Vanguard Information Technology ETF iShares Russell 2000 ETF Technology Select Sector SPDR ETF iShares Russell 1000 Value ETF

    Curated Portfolios (Vests)

    Moat Bitcoin Vest SAAS Multi-Asset Class - Aggressive Multi-Asset Class - Moderate Multi-Asset Class - Conservative Digital Cash Deglobalization Vest BlackRock Smart Beta Aging Vest Swensen Portfolio All Weather

    Others

    Calculators Terms and conditions Privacy Policy Everything Legal
    • 1Top 25 as per Marketwatch
    • 2Top 10 US Stocks from S&P 500 index as per market capitalization
    • 1Total number of KYCed accounts on Vested as of November 2023
    • 2The above portfolio is not meant to represent any real person's portfolio or a suggested portfolio but to show what a typically diversified portfolio might look like
    • 3US Stocks and ETFs are powered by VF Securities, Inc (Member FINRA/SIPC)

    Risk Disclosure - US Markets

    Global

    Vested Finance Inc. is an investment adviser in California. Vested Finance Inc. is registered with the Securities and Exchange Commission (SEC). Registration of an investment adviser dVested Finance Inc. is an investment adviser in California. Vested Finance Inc. is registered with the Securities and Exchange Commission (SEC). Registration of an investment adviser does not imply any specific level of skill or training and does not constitute an endorsement of the firm by the Commission. Vested Finance Inc. only transacts business in states in which it is properly registered or is excluded or exempted from registration. A copy of Vested Finance Inc.’s current written disclosure brochure filed with the SEC which discusses among other things, Vested Finance Inc.’s business practices, services and fees, is available through the SEC’s website at: www.adviserinfo.sec.gov. You can also find a copy of our customer relationship summary (Form CRS) here.

    All securities are offered through VF Securities, Inc. (member FINRA/SIPC). More information about this firm can be found at www.brokercheck.finra.org and at SIPC.org. This website is maintained and published by Vested Finance Inc. Vested Finance Inc., VF Securities Inc., and Vested Private Services Limited are wholly owned subsidiaries of Vested Holding Corp., referred to herein as Vested Group. You can learn more about VF Securities, Inc. on FINRA’s Broker.… Read more

    All investing carries risk. Past performance is not indicative of future returns, which may vary. Investments in stocks and Exchange Traded Funds (“ETFs”) may decline in value. Online trading has inherent risk due to system response and access times that may be affected by various factors, including but not limited to market conditions and system performance. An investor should understand such facts before trading. The risks associated with investing in international securities [including US-listed American Depositary Receipts (“ADRs”) and ETFs that contain non-US securities include, among others, country/political risk relating to the government in the home country; exchange rate risk if the country’s currency is devalued; and inflationary/purchasing power risks if the currency of the home country becomes less valuable as the general level of prices for goods and services rises.

    The information and services provided on this website are not provided to and may not be used by any person or entity in any jurisdiction where the provision or use thereof would be contrary to applicable laws, rules or regulations of any governmental authority or regulatory or self-regulatory organization or where Vested Group is not authorized to provide such information or services.

    All information published on this website is for informational purposes only and no part of it must be construed as an offer to sell or buy a security.

    No information published on the website is intended to be investment advice, portfolio management or as any form of research analysis, directly or indirectly. Each DIY Vest is created by individual users of this website, and Vested Group does not have any role in the selection of stocks for DIY Vests. The users of the website shall be solely responsible for any action taken by them pursuant to the information contained herein, including any investment decision with respect to transaction in securities for which a platform is made available on this website.

    Vested Group makes no warranty or representation, either express or implied, on any product or service offered through its website/platform. Vested Group shall not be liable in any manner whatsoever for any damage or loss, whatsoever caused, in connection with the services provided on this website/platform. Hyperlinks or external websites which may be accessed through this website, if any, are for the user’s convenience and Vested Group does not take any responsibility for the same. Any description of, reference to, or links to other products, publications or services does not constitute an endorsement, authorization, solicitation, advertisement, sponsorship by or affiliation with Vested Group with respect to any linked site or its sponsor, unless expressly stated by Vested Group. While reasonable care has been exercised to ensure that the information published on this website is adequate and reliable, no representation is made by Vested Group as to its accuracy, completeness, or fitness for any purpose and Vested Group, its affiliates, subsidiaries, and employees accept no liability of whatsoever nature for any direct or consequential loss, including without limitation any loss of profits, arising from reliance on this information.

    Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investors’ sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor.

    Read less

    Risk Disclosure - Indian Markets

    india

    P2P lending and INR Bonds are offered through Vested Services Private Limited. Such investments are subject to risks including loss of principal.

    If you have any questions about this disclaimer or in relation to information and services provided through this website, please contact us at help@vestedfinance.co / +919513375607 while providing your contact details for us to correspond further, if required. We welcome your questions and suggestions about us.

     

    By using our website, you agree to our terms and privacy policy.

    Scroll to Top